A Prospective, Observational, Multicenter Study to Determine the Effectiveness and Safety of Glucosamine and Undenatured Collagen Type II Combination (Rejoint MaxÂ®) in Indian Patients with Osteoarthritis of Knee

Abbott Healthcare Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Male and female patient >40 years of age, with primary knee OA (bilateral) of the knee as per the American College of Rheumatology criteria and Kellgren-Lawrence system.
•2.Patient who have been recommended Rejoint Max as per physician discretion without any additional NSAIDs.
•3.Patients presenting with symptoms of OA of knee, expressed continuously or intermittently over the last 6-months prior to screening
•4.Patients with pain VAS > 40/100 mm

•1.Patients with history or presence of active rheumatic disease
•2.Patients with serious concomitant systemic diseases, peripheral or central neurological disorder, severe cardiac/renal/hepatic condition, severe inflammation of joints, hematologic disease joint deformities, secondary OA, fibromyalgia, bursitis, and tendonitis
•3.Patients on oral treatment with glucosamine/chondroitin/other natural health products within the last month
•4.Pregnant and lactating females
•5.Patients with any medical condition judged by investigators that warrant exclusion

发起方